Bone biopsy market size to increase by USD 76.77 million between 2022 and 2027, Technavio

NEW YORK, March 26, 2024 /PRNewswire/ -- The bone biopsy market size is projected to witness substantial growth in the coming years, fueled by factors such as the increasing prevalence of cancer, advancements in minimally invasive biopsy techniques, and the adoption of innovative imaging technologies. According to a recent report, the market is estimated to expand by USD 76.77 million, with a compound annual growth rate (CAGR) of 7.74% between 2022 and 2027.

For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sample

Key Market Trends and Drivers

Needle biopsy procedures, including core needle biopsy (CNB) and fine-needle aspiration biopsy (FNAB), are witnessing significant demand due to their minimally invasive nature and effectiveness in diagnosing bone cancer. These procedures, performed in outpatient settings, offer quick and accurate assessment without the need for surgery. Moreover, the rising prevalence of cancer globally, especially bone cancer, is driving the adoption of biopsy methods for timely diagnosis and treatment planning.

Technological Advancements and Emerging Trends

The market is experiencing a shift towards advanced imaging techniques such as MRI and ultrasound-guided procedures, which offer improved accuracy and reduced invasiveness in diagnosing bone disorders. MRI, in particular, has seen remarkable advancements, providing functional information crucial for accurate diagnosis. Ultrasound techniques like contrast-enhanced ultrasound (CEUS) and real-time ultrasound elastography (RTE) are also being explored to enhance biopsy accuracy.

For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sample

Challenges and Opportunities

While the market shows promising growth prospects, challenges such as the risk of infections associated with biopsy procedures remain significant. However, the adoption of liquid biopsy tests is emerging as a potential solution to mitigate these risks. Additionally, companies in the bone biopsy market are implementing strategic alliances, partnerships, and product innovations to enhance their market presence and cater to evolving customer needs.

Regional Insights

North America is expected to dominate the bone biopsy market, accounting for 38% of global market growth during the forecast period. The region's growth is attributed to factors such as high healthcare technology adoption, increasing healthcare expenditure, and a rising prevalence of bone cancer. Moreover, the presence of leading market players and ongoing technological advancements further drive market growth in North America.

For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sample

Analyst Review

The bone biopsy market plays a crucial role in the diagnosis and treatment of various bone disorders and abnormalities, including bone tumors, cancers, and hematological conditions. With stringent regulatory standards ensuring the quality and safety of medical devices used in biopsy procedures, advancements in technology continue to improve diagnostic accuracy and facilitate targeted treatment strategies for patients worldwide.

Bone biopsies play a critical role in diagnosing a spectrum of abnormalities within the skeletal system, ranging from bone cancers and disorders to infections and tumors. These procedures, often necessitated by persistent pain or suspected malignancies, provide invaluable insights into the underlying causes of discomfort and guide subsequent treatment strategies.

In the realm of oncology, bone biopsies are indispensable tools for identifying and characterizing malignancies such as lymphoma and leukemia. These procedures enable clinicians to obtain tissue samples for histological examination, facilitating accurate diagnosis and personalized treatment planning. With the prevalence of bone-related diseases on the rise, the demand for bone marrow biopsies and other biopsy techniques continues to escalate, propelling growth in the bone biopsy market.

The healthcare sector, including hospitals, clinics, and surgical centers, serves as the primary arena for bone biopsy procedures. Here, medical professionals leverage advanced imaging technologies such as CT-guided biopsies to precisely target areas of concern within the skeletal structure. This synergy between cutting-edge medical devices and clinical expertise underscores the pivotal role of innovation in enhancing diagnostic accuracy and patient outcomes.

However, alongside technological advancements, stringent regulatory policies govern the development and deployment of medical devices used in bone biopsy procedures. Regulatory bodies like the Center for Devices and Radiological Health (CDRH) in the United States ensure that these devices adhere to rigorous safety and efficacy standards. Compliance with such regulations is paramount for manufacturers and healthcare providers alike, fostering trust and confidence in the quality of bone biopsy services.

The bone biopsy market is further shaped by the evolving landscape of bone disorders and cancers. As our understanding of these conditions deepens, so too does the demand for more precise and minimally invasive diagnostic techniques. Consequently, there is a growing emphasis on the development of novel biopsy technologies that offer enhanced accuracy, reduced procedural risks, and improved patient comfort.

Looking ahead, the bone biopsy market is poised for continued expansion, driven by factors such as increasing incidence of bone-related ailments, rising adoption of advanced imaging modalities, and ongoing innovations in medical device technologies. By navigating the intersection of healthcare innovations and regulatory frameworks, stakeholders in the bone biopsy market can unlock new opportunities for improving patient care and advancing diagnostic capabilities in the field of musculoskeletal medicine.

For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sample

Market Overview

As the demand for minimally invasive biopsy procedures and advanced imaging technologies continues to rise, the bone biopsy market presents significant growth opportunities for companies worldwide. With a focus on innovation and strategic partnerships, stakeholders in the market are poised to address evolving customer needs and contribute to the advancement of diagnostic and treatment approaches for bone-related ailments.

The Bone Biopsy Market is experiencing notable growth due to the rising incidence of abnormalities like bone cancers, lymphoma, and leukemia diseases causing debilitating pain. Healthcare sectors are witnessing an upsurge in demand for bone marrow biopsies to diagnose such conditions accurately. However, stringent regulatory policies, overseen by entities like the Center for Devices and Radiological Health, are shaping the market landscape. These regulations ensure the safety and efficacy of bone biopsy procedures, fostering trust among patients and healthcare providers alike. As technology advances, the market is witnessing innovation in biopsy devices and techniques, further propelling its expansion. With an increasing emphasis on early detection and precise diagnosis, the bone biopsy market is poised for sustained growth in the foreseeable future.

For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sample

Related Reports:

• The breast cancer liquid biopsy testing devices market size is expected to increase to USD 730.4 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 23.58%. The market is segmented by type (CTCs and circulating nucleic acids and extracellular vesicles) and geography (North America, Europe, Asia, and Rest of World (ROW)).
• The breast biopsy devices market is estimated to grow at a CAGR of 10.95% between 2022 and 2027. The size of the market is forecast to increase by USD 721.64 million. The market is segmented by product (biopsy needles and systems, biopsy image-guided systems, and others), end-user (hospitals, ASCS, breast cancer specialty centers and clinics, and others), modality (stereotactic x-ray guided breast biopsy, ultrasound-guided breast biopsy, and MRI-guided breast biopsy), and geography (North America, Europe, Asia, and Rest of World (ROW)).

Table of Contents:

1 Executive Summary
2 Landscape
3 Sizing
4 Historic Size
5 Five Forces Analysis
6 Segmentations
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Vendor Landscape
11 Vendor Analysis
12 Appendix

About US
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio